Li Wang

Assistant Professor 

350 Shushanhu Road, Hefei, Anhui, 230031, P.R. China

Tel:+86-551-65591485

Email: wangli@hmfl.ac.cn

EDUCATION BACKGROUND

Sep.2002—Jul.2006
Hubei Institute for Nationalities.
Department of Physics, School of Science,

Sep.2006—Jun. 2008
Huazhong University of Science and Technology
Biophysics, School of Physics,

WORK EXPERIENCE

Jul.2013-present，Assistant Professor, High Magnetic Field Laboratory, Chinese Academy of Sciences.

Jan.2010-Jun.2013，Bioinformatics research group, R&D, Shanghai Center for Bioinformation Technology.

Jul.2008-Jan.2010, Bioinformatics research group, R&D, Wyeth China

 

PUBLICATONS

  1. Zheng Zhao, Hong Wu, Li Wang, Yi Liu, Stefan Knapp, Qingsong Liu, Nathanael S. Gray, Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery? ACS. Chem. Biol, 2014, Jun 20; 9(6):1230-1241.
  2. Wu Hong﹟, Hu Chen﹟, Wang Aoli﹟, E L Weisberg﹟, Wang Wenchao, Chen Cheng, Zhao Zheng, Yu Kailin, Liu Juan, Wu Jiaxin, A Nonami, Wang Li, Wang Beilei, R M Stone, S Liu, J D Griffin, Liu Jing﹡, Liu Qingsong﹡, Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML, Leukemia , 2015 ,Jul 3. doi: 10.1038/leu.2015.175.
  3. Hong Wu﹟, Chen Hu﹟, Aoli Wang﹟, Ellen L， Weisberg﹟, Yongfei Chen﹟, Cai-Hong Yun, Wenchao Wang, Yan Liu, Xiaochuan Liu, Bei Tian, Jinhua Wang, Zheng Zhao, Yanke Liang, Binhua Li, Li Wang, Beilei Wang, Cheng Chen, Sara J. Buhrlage, Ziping Qi, Fengming Zou, Atsushi Nonami, Yuyang Li, Stacey M Fernandes, Sophia Adamia, Richard M. Stone, Ilene A. Galinsky, Xianhuo Wang, Guang Yang, James D. Griffin, Jennifer R. Brown, Michael J. Eck, Jing Liu﹡, Nathanael S. Gray﹡, Liu Qingsong﹡, Discovery of a BTK/MNK Dual Inhibitor for Lymphoma and Leukemia, Leukemia, 2015, Jul 13. doi:10.1038/leu.2015.180.
  4. Hong Wu﹟, Aoli Wang﹟, Wei Zhang﹟, Beilei Wang﹟, Cheng Chen﹟, Wenchao Wang, Chen Hu, Zi Ye, Zheng Zhao, Li Wang, Xixiang Li, Kailin Yu, Juan Liu, Jiaxin Wu, Xiao-E Yan, Peng Zhao, Jinhua Wang, Chu Wang, Ellen L, Weisberg, Nathanael S. Gray, Cai-Hong Yun, Jing Liu﹡, Liang Chen﹡, Liu Qingsong﹡, Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells, Oncotarget, 2015, Oct 13;6(31):31313-31322.
  5. Xixiang Li﹟, Aoli Wang﹟, Kailin Yu﹟, Ziping Qi﹟, Cheng Chen, Wenchao Wang, Chen Hu, Hong Wu, Jiaxin Wu, Zheng Zhao, Juan Liu, Fengming Zou, Li Wang, Beilei Wang, Wei Wang, Shanchun Zhang, Jing Liu*,Liu Qingsong*, “Discovery of (R)-1-(3-(4-amino-3-(4-phen- oxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.” J. Med. Chem., 2015, 58, 9625-9638.
  6. Xiaofei Liang﹟, Xiaochuan Liu﹟, Beilei Wang﹟, Fengming Zou﹟, Aoli Wang, Shuang Qi, Cheng Chen, Zheng Zhao, Wenchao Wang, Ziping Qi, Fengchao Lv, Zhenquan Hu, Li Wang, Shanchun Zhang, Qingsong Liu﹡, Jing Liu﹡, Discovery of 2-((3-amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a potent, selective and orally available BCR-ABL/SRC/p38 kinase inhibitor for Chronic Myeloid Leukemia., J. Med. Chem., 2016, (Publication Date (Web): January 20, 2016) | DOI: 10.1021/acs.jmedchem.5b01618.

 

PATENTS

  1. Ibrutinib is sensitive to FLT3-ITD dependent AML.  inverntors: Liu, Qingsong; Liu Jing; Wu Hong; Hu Chen; Wang Aoli; Wang Wenchao; Chen Cheng; Li Xixiang; Zhao Zheng; Wang Li; Wang Beilei；专利受理号：PCT/CN2014/091375
  2. 发明名称：依鲁替尼的新用途；发明人：刘青松，刘静，王蓓蕾，王傲莉，吴宏，胡晨，王文超，陈程，王黎，李希祥；专利受理号：201410258423.3
  3. 发明名称：依鲁替尼对FLT3-ITD突变的急性白血病的应用；发明人：刘青松，刘静，吴宏， 胡晨，王傲莉，王文超，陈程，李希祥，赵铮，王黎，王蓓蕾；专利受理号： 201410598948.1
  4. 发明名称：一种新型结构的激酶抑制剂；发明人：刘青松，刘静，王强，刘飞扬，王蓓蕾， 王傲莉，王文超，胡晨，陈程，赵铮，吴宏，王黎 ；专利受理号：201410757626.7
  5. 发明名称：一种新型的 PI3K 激酶抑制剂；发明人：刘青松，刘静，张欣，梁小飞，刘晓川， 刘娟娟，陈程，赵铮，王傲莉， 王文超，吴宏，王蓓蕾，王黎；专利受理号： 201410821908.9
  6. 发明名称：FLT3激酶的新型抑制剂及其用途；发明人：刘静，刘青松，李希祥，王傲莉，吴 宏，陈程，王文超，胡晨，赵铮，吴佳昕，刘娟，余凯琳，王伟，王黎，王蓓蕾；专利受理号：201510028177.7